tbuckley/cabot-search huggingface dataset:
Self-efficacy and risk of persistent shoulder pain: results of a Classification and Regression Tree (CART) analysis
Authors: Rachel Chester, Mizanur Khondoker, Lee Shepstone, Jeremy S Lewis, Christina Jerosch-Herold
Journal: British Journal of Sports Medicine (2019)

Objectives To (i) identify predictors of outcome for the physiotherapy management of shoulder pain and (ii) enable clinicians to subgroup people into risk groups for persistent shoulder pain and disability. Methods 1030 people aged ≥18 years, referred to physiotherapy for the management of musculoskeletal shoulder pain were recruited. 810 provided data at 6 months for 4 outcomes: Shoulder Pain and Disability Index (SPADI) (total score, pain subscale, disability subscale) and Quick Disability of the Arm, Shoulder and Hand (QuickDASH). 34 potential prognostic factors were used in this analysis. Results Four classification trees (prognostic pathways or decision trees) were created, one for each outcome. The most important predictor was baseline pain and/or disability: higher or lower baseline levels were associated with higher or lower levels at follow-up for all outcomes. One additional baseline factor split participants into four subgroups. For the SPADI trees, high pain self-efficacy reduced the likelihood of continued pain and disability. Notably, participants with low baseline pain but concomitant low pain self-efficacy had similar outcomes to patients with high baseline pain and high pain self-efficacy. Cut-off points for defining high and low pain self-efficacy differed according to baseline pain and disability. In the QuickDASH tree, the association between moderate baseline pain and disability with outcome was influenced by patient expectation: participants who expected to recover because of physiotherapy did better than those who expected no benefit. Conclusions Patient expectation and pain self-efficacy are associated with clinical outcome. These clinical elements should be included at the first assessment and a low pain self-efficacy response considered as a target for treatment intervention.
Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC
Authors: Mei-Mei Zheng, Yang-Si Li, Ben-Yuan Jiang, Hai-Yan Tu, Wen-Fang Tang, Jin-Ji Yang, Xu-Chao Zhang, Jun-Yi Ye, Hong-Hong Yan, Jian Su, Qing Zhou, Wen-Zhao Zhong, Xue-Ning Yang, Wei-Bang Guo, Shannon Chuai, Zhou Zhang, Hua-Jun Chen, Zhen Wang, Chao Liu, Yi-Long Wu
Journal: Journal of Thoracic Oncology (2019)
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology &amp; Hepatology Commission
Authors: Graham S Cooke, Isabelle Andrieux-Meyer, Tanya L Applegate, Rifat Atun, Jessica R Burry, Hugo Cheinquer, Geoff Dusheiko, Jordan J Feld, Charles Gore, Max G Griswold, Saeed Hamid, Margaret E Hellard, JinLin Hou, Jess Howell, Jidong Jia, Natalia Kravchenko, Jeffrey V Lazarus, Maud Lemoine, Olufunmilayo A Lesi, Liudmyla Maistat, Brian J McMahon, Homie Razavi, Teri Roberts, Bryony Simmons, Mark W Sonderup, C Wendy Spearman, Bridie E Taylor, David L Thomas, Imam Waked, John W Ward, Stefan Z Wiktor, Ayman Abdo, Rakesh Aggarwal, Alessio Aghemo, Bandar Al-Judaibi, Mamun Al Mahtab, Arshad Altaf, Zyaad Ameen, Tarik Asselah, Oidov Baatarkkhuu, Ella Barber, Eleanor Barnes, Pascale Boulet, Louise Burrows, Maia Butsashvili, Erica Chan, Chelsea Chow, Ben Cowie, Chris Cunningham, Alexandre de Araujo, Graciela Diap, Greg Dore, Joseph Doyle, Manal Elsayed, Emmanuel Fajardo, Ed Gane, Aneley Getahun, David Goldberg, Tiffany Got, Matthew Hickman, Andrew Hill, Sharon Hutchinson, Chris Jones, Saleem Kamili, Amreen Khan, Alice Lee, Tin Yan Lee, Jioiji Malani, Tammy Meyers Morris, Shevanthi Nayagam, Richard Njouom, Ponsiano Ocama, Alisa Pedrana, Rosanna Peeling, Amulya Reddy, Jilian Sacks, Shiv Sarin, Yusuke Shimakawa, Marcela Silva, Pavlo Skala, Simon Taylor-Robinson, Alex Thompson, Mark Thursz, Alfred Tonganibeia, Jack Wallace, James Ward, Fernando Wolff, Peter Vickerman, Johnny Yau
Journal: The Lancet. Gastroenterology & hepatology (2019)
Addressing immune-related adverse events of cancer immunotherapy: how prepared are rheumatologists?
Authors: Marie Kostine, Laura C Cappelli, Cassandra Calabrese, Leonard H Calabrese, Clifton O Bingham, Christophe Richez, Jacques-Eric Gottenberg, Olivier Lambotte
Journal: Annals of the Rheumatic Diseases (2019)

Cancer immunotherapy blocking immune checkpoints represents a major advance in oncology. Immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death 1 (PD-1) or its ligand PD-L1 have become standard of care in many advanced-stage cancers. Yet an important proportion of patients experience inflammatory or autoimmune side effects, also known as immune-related adverse events (irAEs), as a consequence of dysregulated immunity. irAEs can affect almost any organ system.1 Notably, an expanding range of manifestations mimicking our classical rheumatic diseases have been described.2 3 Rheumatic irAEs, including inflammatory arthritis, pseudomyalgia rheumatica, sicca syndrome, myositis and vasculitis, are increasingly reported. Since there has been increasing emphasis on this emerging field within the last 3 years, we aimed to evaluate the knowledge of rheumatologists, as well as other specialists, regarding ICI and irAEs through an online survey.

Survey questions addressed the demographics (gender, age, practice setting and duration of medical practice), domains of awareness, clinical experience and interest in irAE-specific medical education. The survey was first distributed in the USA (2016) to healthcare provider cohorts at Johns Hopkins University (JHU) and Cleveland Clinic (CC), then in France (2018) to rheumatologists and other specialists via …
Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry
Authors: Taimur T. Shah, Max Peters, David Eldred-Evans, Saiful Miah, Tet Yap, Nicholas A. Faure-Walker, Feargus Hosking-Jervis, Benjamin Thomas, Tim Dudderidge, Richard G. Hindley, Stuart McCracken, Damian Greene, Raj Nigam, Massimo Valerio, Suks Minhas, Mathias Winkler, Manit Arya, Hashim U. Ahmed
Journal: European Urology (2019)
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study
Authors: René-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, Julien Lazarovici, Hervé Ghesquieres, Aspasia Stamatoullas, Jehan Dupuis, Anne-Claire Gac, Thomas Gastinne, Bertrand Joly, Krimo Bouabdallah, Emmanuelle Nicolas-Virelizier, Pierre Feugier, Franck Morschhauser, Richard Delarue, Hassan Farhat, Philippe Quittet, Alina Berriolo-Riedinger, Adrian Tempescul, Véronique Edeline, Hervé Maisonneuve, Luc-Matthieu Fornecker, Thierry Lamy, Alain Delmer, Peggy Dartigues, Laurent Martin, Marc André, Nicolas Mounier, Alexandra Traverse-Glehen, Michel Meignan
Journal: The Lancet Oncology (2019)
SAT0361 Trabecular bone score in osteogenesis imperfecta. is it useful?
Authors: H. Florez, A. Muxi, E. Gonzalez, A. Monegal, N. Guañabens, P. Peris
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The trabecular Bone Score (TBS) is a novel gray-level textural analysis measurement that can be applied to DXA images to estimate trabecular microarchitecture and has been shown to be related to direct measures of bone microarchitecture and fracture risk. Osteogenesis impefecta (OI) is a congenital bone disease characterised by a low bone mineral density (BMD) and poor bone quality and strength. The usefulness of TBS in OI has been scarcely evaluated. <h3>Objectives</h3> To analyse the clinical usefulness of TBS determination in patients with OI and its relation with anthropometric and clinical features (especially concerning skeletal fractures and BMD results). <h3>Methods:</h3> Twenty-four patients (18 F:6 M) with OI with a mean age of 38±15 years<sup>19–63</sup> attending a Metabolic Bone Disease Unit were included. The clinical reports of the patients were reviewed, with especial attention to the clinical features (weight, height and body mass index [BMI]), previous fractures, disease severity, associated mutations and treatments received. Lumbar spine (LS), total hip (TH), and femoral neck (FN) BMD were measured using DXA equipment (Lunar) in all patients. TBS was analysed in LS, and the results were classified in three categories<sup>1</sup>: TBS &gt;1.310 (normal), TBS 1.230–1.310 (partially degraded microarchitecture), TBS &lt;1.230 (degraded microarchitecture). TBS values were compared with a healthy control group of similar age and gender. <h3>Results:</h3> 5/24 patients (21%) had a degraded microarchitecture, 4 (17%) a partially degraded microarchitecture and 15 (63%) normal TBS. All patients with TBS &lt;1230 were over 40 years old. 21/24 patients had a previous history of multiple fractures. Regarding BMD, 54% of the patients had osteoporosis, 42% osteopenia and one had normal values. Most patients had a mutation in the <i>COL1A1</i> gene (63%). A correlation was observed between TBS and age (r=−0.5, p=0.006) and LS BMD (r=0.5, p=0.014), showing a trend to significance with BMI (r=−0.4, p=0.058). No significant differences were observed on comparing TBS in patients and controls (1.321 vs. 1.391, p=N .S.). <h3>Conclusions:</h3> TBS measurement does not seem to be useful for evaluating bone strength in patients with OI. Despite most patients presenting a history of multiple fractures, only 21% showed degraded microarchitecture with TBS. <h3>Reference:</h3> [1] McCloskey EV, Odén A, Harvey NC, et al. J Bone Miner Res2016;31:940–8. <h3>Disclosure of Interest:</h3> None declared
Update on Aspiration Thrombectomy
Authors: Patrick O’Gara
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
Authors: Sherene Loi, Damien Drubay, Sylvia Adams, Giancarlo Pruneri, Prudence A. Francis, Magali Lacroix-Triki, Heikki Joensuu, Maria Vittoria Dieci, Sunil Badve, Sandra Demaria, Robert Gray, Elisabetta Munzone, Jerome Lemonnier, Christos Sotiriou, Martine J. Piccart, Pirkko-Liisa Kellokumpu-Lehtinen, Andrea Vingiani, Kathryn Gray, Fabrice Andre, Carsten Denkert, Roberto Salgado, Stefan Michiels
Journal: Journal of Clinical Oncology (2019)

Purpose The aim of the current study was to conduct a pooled analysis of studies that have investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) in early-stage triple negative breast cancer (TNBC). Methods Participating studies had evaluated the percentage infiltration of stromally located TILs (sTILs) that were quantified in the same manner in patient diagnostic samples of early-stage TNBC treated with anthracycline-based chemotherapy with or without taxanes. Cox proportional hazards regression models stratified by trial were used for invasive disease-free survival (iDFS; primary end point), distant disease-free survival (D-DFS), and overall survival (OS), fitting sTILs as a continuous variable adjusted for clinicopathologic factors. Results We collected individual data from 2,148 patients from nine studies. Average age was 50 years (range, 22 to 85 years), and 33% of patients were node negative. The average value of sTILs was 23% (standard deviation, 20%), and 77% of patients had 1% or more sTILs. sTILs were significantly lower with older age ( P = .001), larger tumor size ( P = .01), more nodal involvement ( P = .02), and lower histologic grade ( P = .001). A total of 736 iDFS and 548 D-DFS events and 533 deaths were observed. In the multivariable model, sTILs added significant independent prognostic information for all end points (likelihood ratio χ 2 , 48.9 iDFS; P &lt; .001; χ 2 , 55.8 D-DFS; P &lt; .001; χ 2 , 48.5 OS; P &lt; .001). Each 10% increment in sTILs corresponded to an iDFS hazard ratio of 0.87 (95% CI, 0.83 to 0.91) for iDFS, 0.83 (95% CI, 0.79 to 0.88) for D-DFS, and 0.84 (95% CI, 0.79 to 0.89) for OS. In node-negative patients with sTILs ≥ 30%, 3-year iDFS was 92% (95% CI, 89% to 98%), D-DFS was 97% (95% CI, 95% to 99%), and OS was 99% (95% CI, 97% to 100%). Conclusion This pooled data analysis confirms the strong prognostic role of sTILs in early-stage TNBC and excellent survival of patients with high sTILs after adjuvant chemotherapy and supports the integration of sTILs in a clinicopathologic prognostic model for patients with TNBC. This model can be found at www.tilsinbreastcancer.org .
Ruxolitinib, a JAK1/JAK2 Selective Inhibitor Is Highly Efficacious in Corticosteroid Untreated and Refractory MHC-Mismatched Mouse Model of Acute GvHD
Authors: Ashish Juvekar, Bruce Ruggeri, Sindy Condon, Andrew Borkowski, Reid Huber, Paul Smith
Journal: Blood (2018)
Adoptive Transfer of Purified Donor-B-Lymphocytes after Allogeneic Stem Cell Transplantation: Results from a Phase I/IIa Clinical Trial
Authors: Julia Winkler, Hannes Tittlbach, Wolf Roesler, Julian Strobel, Roland Zimmermann, Stefanie Maas, Bernd Spriewald, Daniel Wolff, Roland Repp, Lambros Kordelas, Michael Mach, Andreas Mackensen, Thomas H. Winkler
Journal: Blood (2016)
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials
Authors: Charles S Haworth, Diana Bilton, James D Chalmers, Angela M Davis, Juergen Froehlich, Igor Gonda, Bruce Thompson, Adam Wanner, Anne E O'Donnell
Journal: The Lancet Respiratory Medicine (2019)
THU0696 Is autoimmunity related to nailfold videocapillaroscopy patterns progession? data from a tertiary centre
Authors: L. Torrens, C. Soleto, J.C. Nieto-González
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Nailfold videocapillaroscopy (NVC) is a non-invasive technique that allows to evaluate the structure and distribution of capillaries in the nail microcirculation. <h3>Objectives</h3> Our objective was to investigate the relation between the autoantibodies (Ab) detected in the patients who undergo follow-up NVCs and the progression from lower to higher severity of the NVCs patterns. <h3>Methods</h3> Longitudinal, observational and descriptive study that includes patients with at least two NVCs, between June 2012 and December 2016 in the Rheumatology service of a tertiary centre. We collected demographics data, number of NVCs performed, Ab positivity, as well as the NVCs patterns. The relationship between the basal autoimmunity and the progression of the NVCs patterns during the follow-up period, defining progression from non-specific patterns to patterns of scleroderma to late scleroderma. <h3>Results</h3> 473 patients were included, 115 had two or more NVCs performed, 104 women (90.51%). Of these, 40 (34.78%) had a third NVC, 9 (7.82%) a fourth and only two patients a fifth. Regarding the Ab registered in patients before the first NVC, 27 patients did not present positivity to any Ab (23.47%), 28 had isolated ANA + (24.34%), 33 Anticentromere+with or without ANA (28.69%), 7 patients Anti-scl70 +with or without ANA (6.08%), 10 patients Anti-Ro or Anti-La with or without ANA (8.69) and 10 patients presented other types of antibodies than those mentioned (11.3%). The most frequent pattern in the first NVC was non-specific mild alterations (49 cases) in 42.6%, followed by normal pattern<sup>20</sup> in 17.39%, earlyscleroderma<sup>19</sup> in 16.52%, non-specific moderate lesions<sup>17</sup> and pattern of late scleroderma<sup>10</sup> There was a progression from lower to higher severity in 25 NVCs, 88 mantained a similar pattern and 2 NVCs presented significant regression (table 2). <h3>NVC patterns</h3> Normal (N), non-specific mild alterations (NMI), non-specific moderate lesions (NML), Early scleroderma (ES), Active scleroderma (AS) y Late scleroderma (LS) <h3>Conclusions</h3> Autoimmunity does not seem to influence on the degree of progression of NVCs patterns. The association between positive ANA with anticentrome +or not, it is the most frequently combination related to the progression of such patterns. <h3>References</h3> [1] Cutolo M, Pizzorni C, Secchi ME, Sulli A. Capillaroscopy. Best Pract Res Clin Rheumatol2008Dec;22(6):1093-108 <h3>Disclosure of Interest</h3> None declared
THU0143 Vascular wall inflamation in rheumatoid arthritis patients decreases after 6 months of anti-inflammatory therapy with methotrexate or adalimumab as measured by 18f-fdg-pet/ct
Authors: A. Blanken, R. Agca, A. Voskuijl, R. Boellaard, C. van der Laken, M. Nurmohamed
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) have an elevated cardiovascular (CV) disease risk, mostly explained by both an increased prevalence of traditional CV risk factors and the presence of systemic inflammation that accelerates atherosclerosis. There is accumulating evidence that anti-inflammatory treatment for RA reduces this CV risk. A non-invasive tool for detecting vascular wall inflammation in atherosclerosis is 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (18F-FDG-PET/CT). <h3>Objectives</h3> To study the effect of anti-inflammatory treatment with methotrexate (MTX) or adalimumab on vascular wall inflammation in RA assessed by 18F-FDG-PET/CT. <h3>Methods</h3> 18F-FDG-PET/CT was done in patients with active early RA starting MTX (n=25) and active established RA starting adalimumab (n=24) before and after 6 months of therapy, and in osteoarthritis controls (OA; n=29). 18F-FDG uptake in arterial wall was determined by standardised uptake values (SUV). Volumes of interest covering the arterial segment with the highest 18F-FDG were defined to derive the maximum SUV (SUVmax) in the ascending, descending and abdominal aorta and the aortic arch. Global arterial uptake was estimated using the mean SUVmax of the four arterial segments. <h3>Results</h3> Mean age was 65±9 for early RA, 61±7 for established RA and 63±5 years for OA controls. Median disease duration was 2.1 (interquartile range (IQR) 1.3–3.3) weeks for early RA and 6.9 (IQR 1.8–13.9) years for established RA. DAS28 was 4.9±1.0 and 4.4±1.0 at baseline and declined to 3.1±1.3 and 2.8±1.4 after 6 months therapy, respectively. At baseline mean SUVmax was 1.86±0.38 for early RA, 1.68±0.43 for established RA and 1.56±0.41 for OA controles. SUVmax tended to decline more in early RA patients when compared to established RA (1.86±0.38 to 1.79±0.43 (-3.7%) and 1.68±0.43 to 1.63±0.43 (-3.0%), respectively). SUVmax in most arterial segments declined after 6 months of therapy (table 1). The most prominent decline in SUVmax was in de abdominal aorta in established RA patients (−9.8%). <h3>Conclusions</h3> A decline in global arterial SUVmax and in most of arterial segments was found in both early and established RA patients after 6 months of MTX and/or adalimumab, suggesting that anti-inflammatory therapy with either MTX and/or adalimumab decreases arterial wall inflammation and thus CV risk in RA. <h3>Disclosure of Interest</h3> None declared
SAT0680 The development and validation of interstitial lung disease prediction models in three international mixed connective tissue disease cohorts: the norwegian mctd cohort, the hungarian mctd cohort and the mctd cohort from minnesota, us
Authors: S. Reiseter, P. Ungprasert, R. Gunnarsson, Ø. Molberg, M.B. Lund, T.M. Aaløkken, P. Szodoray, E. Bodolay
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Mixed Connective Tissue Disease (MCTD) is characterised by the presence of anti-RNP antibodies with clinical features also found in SSc, SLE and IIM. There is an ongoing debate of MCTD's position as a CTD. A substancial proportion of MCTD patients develop Interstitial Lung Disease (ILD). <h3>Objectives</h3> This study was conducted with the aims to explore the value of MCTD diagnosis and risk assessment by developing and validating ILD prediction models. <h3>Methods</h3> Multivariable logistic regression analyses were performed in 3 international MCTD cohorts. ILD prediction model development from clinical and laboratory parameters was performed in the Norwegian MCTD cohort (n=119). External validation of the models were performed in the Hungarian MCTD cohort (n=196) and the MCTD cohort from Minnesota, US (n=50). ILD was diagnosed by chest CT examination. <h3>Results</h3> The cohort characteristics are presented in table 1. An ILD prediction model including Pulmonary Function Test (PFT) results (table 2) and excluding PFT results was developed. The Hosmer-Lemeshow goodness of fit test (HL test) was. 31 and. 71 and the ROC was. 83 and. 78 respectively. The ILD prediction model including DLCO &lt;60% was validated in the Hungarian MCTD cohort and showed good calibration and discrimination (HL test=0.95 and ROC=0.82). The ILD prediction model excluding PFT results showed good calibration and discrimination in both the Hungarian MCTD cohort (HL test=0.72 and ROC=0.80) and the MCTD cohort from Minnesota (HL test=0.96 and ROC=0.67). <h3>Conclusions</h3> The cohorts have different characteristics. Despite these differences the ILD prediction models developed in the Norwegian MCTD cohort have shown external validity when assessed in the Hungarian MCTD cohort and the MCTD cohort from Minnesota. Risk factors of ILD in MCTD patients are high levels of anti-U1 RNP antibodies, absence of arthritis and increasing age. The successive ILD prediction across different MCTD cohorts strengthens the value of MCTD diagnosis and anti-RNP antibody detection in clinical practice. <h3>Disclosure of Interest</h3> None declared